TRIA Bioscience is a biotechnology company advancing innovative treatments for infection and chronic disease" discovering and developing diagnostics, vaccines and immunotherpeutics for the detection and treatment of infectious diseases worldwide. Conjugate vaccines are among the most successful vaccines developed to date - very effective in preventing pneumonia and meningitis and inducing antibodies to bacterial polysaccharides - requiring the chemical conjugation of weak antigens to a protein carrier to improve immunogenicity. However, though successful, conjugate vaccines are expensive to manufacture, and the protein carriers and conjugation reactions create problems that diminish vaccine activity. New conjugate vaccines for infectious disease have not been approved, nor has this approach succeeded in treating diseases that use other weak antigens including carbohydrates, short peptides, and small molecule drugs. In this context, TRIA Bioscience is pioneering a new approach to conjugate vaccines where traditional protein carriers are replaced with a much smaller synthetic peptide and antigens are attached using new proprietary methods. These vaccines are very simple in design and their manufacturing generates a cost-effective product unmatched by current technologies.
